HC Wainwright Forecasts OptiNose FY2029 Earnings

OptiNose, Inc. (NASDAQ:OPTN) – HC Wainwright issued their FY2029 earnings estimates for OptiNose in a research report issued to clients and investors on Friday, January 3rd. HC Wainwright analyst M. Caufield expects that the company will earn $1.41 per share for the year. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for OptiNose’s current full-year earnings is ($0.20) per share.

Separately, Piper Sandler reduced their price objective on OptiNose from $45.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th.

OptiNose Trading Down 2.6 %

NASDAQ:OPTN opened at $5.96 on Monday. The firm has a market capitalization of $59.96 million, a PE ratio of -21.28 and a beta of -0.15. OptiNose has a 52 week low of $4.82 and a 52 week high of $31.50. The stock has a 50 day moving average of $7.69 and a 200-day moving average of $11.70.

Institutional Investors Weigh In On OptiNose

Hedge funds have recently made changes to their positions in the business. Stonepine Capital Management LLC acquired a new stake in OptiNose in the 2nd quarter valued at approximately $2,444,000. Great Point Partners LLC increased its holdings in shares of OptiNose by 56.2% during the second quarter. Great Point Partners LLC now owns 13,727,097 shares of the company’s stock valued at $14,276,000 after purchasing an additional 4,940,779 shares during the period. XTX Topco Ltd bought a new stake in shares of OptiNose during the second quarter valued at about $88,000. Squarepoint Ops LLC lifted its holdings in OptiNose by 173.7% in the second quarter. Squarepoint Ops LLC now owns 171,610 shares of the company’s stock worth $178,000 after purchasing an additional 108,903 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its position in OptiNose by 2.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,920,309 shares of the company’s stock valued at $3,037,000 after buying an additional 81,233 shares in the last quarter. Institutional investors own 85.60% of the company’s stock.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.